Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)

October 2019

Questions will pop up about the safety of Janus kinase (JAK) inhibitors...Xeljanz, Olumiant, and the newly approved Rinvoq.

There's an uptick in use of JAK inhibitors for rheumatoid arthritis and other autoimmune diseases...because they're oral.

But these meds may fly under your radar if you're not prescribing them...and they're not on your EHR med list.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

E-Cigarettes Emphasize Risks of Vaping and Help Kids and Teens Stop
Influenza Share the Latest Advice About 2019-2020 Influenza Immunizations
Practice Demystify the Ins and Outs of Compression Stockings
Anticoagulants Be Prepared to Manage Direct Oral Anticoagulants Around Surgery
Pediatrics Weigh Options for Managing Type 2 Diabetes in Kids
Contraceptives Don't Jump to the New Progestin-Only Oral Contraceptive, Slynd (Drospirenone)
Immunosuppressives Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)
Vaccines Know When to Discuss HPV Vaccination With Adults Over Age 26
Antibiotics Save the Antibiotic Xenleta as a Last Resort
Medicare Be Familiar With Changes Coming to Medicare Part D in 2020
IBS Watch for Zelnorm's Return for Irritable Bowel Syndrome With Constipation
Fungal Infections Avoid Empiric Fluconazole for Candida auris